PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
PERRIGO Co plc
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$16.09−0.54 (-3.25%)
Close on Oct 19, 2026
- Market cap
- $2.25B
- P/E (TTM)
- –
- Dividend yield
- 7.21%
Share price
−$5.53 (−25.58%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
PERRIGO Co plc saw revenue fall 4.2% to $4.14B over the twelve months to Jun 27, 2026. Operating income fell 644.9% to -$1.56B, moving the operating margin from 6.6% to -37.7%. Free cash flow was $119.30M, down 53.5% from a year earlier.
Revenue
$4.14B
-4.2% vs. a year earlier
Operating income
-$1.56B
-644.9% vs. a year earlier
Free cash flow
$119.30M
-53.5% vs. a year earlier
EPS, diluted
-$12.60
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 27, 2026
Valuation
- Market cap
- $2.25B
- P/E ratio
- –
- Price to sales
- 0.54
- Price to book
- 0.89
- Dividend yield
- 7.21%
- Free cash flow yield
- 5.31%
Fundamentals
- Revenue
- $4.14B
- Net income
- -$1.73B
- EPS, diluted
- -$12.60
- Free cash flow
- $119.30M
- Book value per share
- $18.02
- Diluted shares
- 140M
Twelve years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$4.14B-4.2% YoY
Gross profit
$1.38B-10.8% YoY
Operating income
-$1.56B-644.9% YoY
Net income
-$1.73B
EPS, diluted
-$12.60
Free cash flow
$119.30M-53.5% YoY
Reported periodTrailing twelve months